Insulin resistance linked with increased cardiovascular risk not kidney risk in diabetes patients: Study

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-04-30T10:00:34+05:30 | Updated On 30 April 2024 12:29 PM IST

A recent study published in the Journal of Diabetes Care investigated the association between insulin resistance, cardiorenal risk and the effectiveness of finerenone to the management of type 2 diabetes.

This FIDELITY study involved a total of 13,026 patients with type 2 diabetes and examined whether insulin resistance, measured by estimated glucose disposal rate (eGDR), influence the risk of cardiovascular and kidney complications. Furthermore, if the risk affected the effectiveness of finerenone when compared to a placebo was examined.

The results showed that patients with lower eGDR had a significantly higher incidence of cardiovascular events compared to those with higher eGDR, irrespective of treatment that indicates insulin resistance. The incidence rate of cardiovascular events per 100 patient-years for finerenone was 5.18 and for placebo was 6.34 in the lower eGDR group, versus 3.47 for finerenone and 3.76 for placebo in the higher eGDR group.

There was no significant association found between eGDR and kidney outcomes. Also, the study revealed that the efficacy of finerenone in reducing cardiovascular and kidney complications was consistent across patients with different levels of insulin resistance.

The findings underscore the importance of considering insulin resistance as a significant risk factor for cardiovascular events in patients with type 2 diabetes. While insulin resistance was not associated with kidney outcomes in this study, it remains as a crucial factor in assessing overall cardiorenal risk.

The outcomes provide valuable insights into the complex interplay between insulin resistance, cardiovascular risk and medication efficacy in individuals with type 2 diabetes. Understanding these relationships can improve more targeted treatment strategies for patients with this chronic condition.

Source:

Ebert, T., Anker, S. D., Ruilope, L. M., Fioretto, P., Fonseca, V., Umpierrez, G. E., Birkenfeld, A. L., Lawatscheck, R., Scott, C., Rohwedder, K., & Rossing, P. (2023). Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance. In Diabetes Care. American Diabetes Association. https://doi.org/10.2337/dc23-1420

Diabetes Care Journalinsulin resistanceCardiovascular risk

Source : Diabetes Care

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751